Chromosomal imbalances associated with response to chemotherapy and cytotoxic cytokines in human malignant glioma cell lines

International Journal of Cancer

Volumn 91, Issue 2, 2001, Pages 213-218

  Weber, Ruthild G ^a,d   Rieger, Johannes ^b   Naumann, Ulrike ^b   Lichter, Peter ^c   Weller, Michael ^c  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Chemoresistance; Chemosensitivity; Chemotherapy; Chromosomal aberrations; Comparative genomic hybridization; Glioma

Indexed keywords

CAMPTOTHECIN; CASPASE; CYCLINE; CYTARABINE; FAS ANTIGEN; PACLITAXEL; PROTEIN BCL 2; PROTEIN KINASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE G2 PHASE; CHEMOSENSITIVITY; CHROMOSOME 1; CHROMOSOME 17Q; CHROMOSOME 19; CHROMOSOME 20Q; CHROMOSOME MAP; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; GENE MUTATION; GLIOBLASTOMA; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; NEUROSURGERY; POSTOPERATIVE CARE; PRIORITY JOURNAL;

EID: 0035863372     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(200002)9999:9999<::aid-ijc1036>3.3.co;2-d     Document Type: Article

References (42)

1. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors
2. Detection of complete and partial chromosome gains and losses by comparative genomic in situ hybridization
3. Chromosomal abnormalities in glioblastoma multiforme tumors and glioma cell lines detected by comparative genomic hybridization
4. Detection of multiple gains and losses of genetic material in ten glioma cell lines by comparative genomic hybridization
5. Analyses of brain tumor cell lines confirm a simple model of relationships among fluorescence in situ hybridization, DNA index, and comparative genomic hybridization
6. Genomic changes in glioblastoma cell lines detected by comparative genomic hybridization
7. Comparative genomic hybridization of human malignant gliomas reveals multiple amplification sites and nonrandom chromosomal gains and losses
8. Characterization of genomic alterations associated with glioma progression by comparative genomic hybridization
9. Clinically distinct subgroups of glioblastoma multiforme studied by comparative genomic hybridization
10. Gliomas in families: Chromosomal analysis by comparative genomic hybridization
11. APO2 ligand: A novel lethal weapon against malignant glioma?
12. Predicting chemoresistance in human malignant glioma cells: The role of molecular genetic analyses
13. ARF, PTEN tumor suppressor genes in human glioma cell lines
14. Detection of chromosomal aberrations by means of molecular cytogenetics: Painting of chromosomes and chromosomal subregions and comparative genomic hybridization
15. Quantitative analysis of comparative genomic hybridization
16. Minimal size of deletions detected by comparative genomic hybridization
17. Detection of amplified genomic sequences by reverse chromosome painting using genomic tumor DNA as probe
18. Computer image analysis of comparative genomic hybridization
19. Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human malignant glioma cells. Induction and modulation of sensitivity by cytokines
20. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults
21. Malignant glioma: Who benefits from adjuvant chemotherapy?
22. Association of genomic imbalances with resistance to therapeutic drugs in human melanoma cell lines
23. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas
24. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic losses on chromosome arms 19q and 1p
25. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization
26. Allelotype of human malignant astrocytoma
27. Molecular pathogenesis of malignant gliomas
28. CD95(APO-1/Fas)-mediated apoptosis in normal and malignant liver, colon, and hematopoietic cells
29. Death ligand/receptor-independent caspase activation mediates drug-induced cell death in malignant glioma cells
30. RAIDD is a new 'death' adaptor molecule
31. Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene
32. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated
33. Amplification and expression of cyclin D genes (CCND 1, CCND2 and CCND3) in human malignant gliomas
34. Gliomas
35. Cyclins A and B1 in the human cell cycle
36. A novel cyclin associates with MO15/CDK7 to form the CDK-activating kinase
37. Growth inhibition induced by Ro 31-8220 and calphostin C in human glioblastoma cell lines is associated with apoptosis and inhibition of CDC2 kinase
38. K252a induces cell cycle arrest and apoptosis by inhibiting Cdc2 and Cdc25c
39. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF
40. TL1, a novel tumor necrosis factor-like cytokine? induces apoptosis in endothelial cells: Involvement of activation of stress protein kinases (stress-activated protein kinase and p38 mitogen-activated protein kinase) and caspase-3-like protease
41. Identification of a novel serine/threonine kinase and a novel 15-kD protein as potential mediators of the gamma interferon-induced cell death
42. Analysis of the p53 gene and its expression in human glioblastoma cells